CONMED stock centers on its medical device platform
CONMED Corp (CNMD) is a US-listed medical technology company specializing in surgical and orthopedic devices. Its business model relies on procedure-based demand and recurring hospital use, with revenue tied to procedure volumes and hospital budgets. The stock trades on Nasdaq and is influenced by earnings visibility, reimbursement trends, and operating leverage within the healthcare sector.
Director Jeffrey Mirviss granted 5,603 RSUs at CONMED (NYSE: CNMD)
CONMED Corp director Jeffrey B. Mirviss was granted 5,603 restricted stock units (RSUs), which represent a contingent right to receive one share of common stock per RSU. These RSUs were awarded under the company's 2025 Long-Term Incentive Plan and are set to vest 100% after one year. This transaction is categorized as a compensation-related equity award rather than an open-market purchase or sale.
Director at CONMED (CNMD) receives grant of 5,603 restricted stock units
CONMED Corp director Celine Christine Martin was granted 5,603 restricted stock units (RSUs) as equity compensation, with each RSU representing a contingent right to receive one share of CONMED common stock. The RSUs were awarded at $0.00 per unit under the company’s 2025 Long-Term Incentive Plan and generally vest 100% after one year. This Form 4 filing details the transaction, showing Martin's RSU holdings after the grant total 5,603 units.
Form 4 CONMED Corporation For: 2 July By Investing.com
This article announces the publication of a Form 4 for CONMED Corporation on July 2nd. The content primarily consists of navigation links and market data, with the core informational part being the Form 4 announcement itself.
New CONMED (CNMD) director Celine Christine Martin reports no common stock holdings
CONMED Corp's new director, Celine Christine Martin, has filed an initial Form 3 reporting no direct holdings of the company's common stock. She became a director on July 1, 2026, and this filing establishes a baseline for tracking any future changes in her ownership. The Form 3 is an initial statement and does not indicate any insider buying or selling.
New CONMED (CNMD) director Jeffrey Mirviss reports no common stock holdings
CONMED Corp director Jeffrey B. Mirviss, who joined the board on July 1, 2026, has filed an initial insider ownership report (Form 3). The filing indicates that Mirviss holds 0 shares of the company's Common Stock, thus reporting no beneficial ownership at this time. This report details his initial status as an insider without any reported transactions.
CONMED schedules Q2 results call for July 29 after market close
CONMED Corporation (NYSE: CNMD) announced it will report its Q2 2026 financial results after the market closes on Wednesday, July 29, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Interested parties can pre-register for the call or access the webcast via CONMED's investor relations website.
Why CONMED (CNMD) Shares Are Falling Today
CONMED (NYSE:CNMD) shares fell 4.9% after BofA Securities downgraded the stock to Underperform from Neutral, citing concerns about future growth and lowering its 2027 organic growth and EPS estimates. The firm maintained a $40.00 price target. This follows an earlier drop linked to a U.S. Commerce Department investigation into medical equipment imports that could lead to tariffs.
BofA downgrades Conmed stock rating on growth concerns
BofA Securities has downgraded Conmed (NYSE:CNMD) to Underperform from Neutral, maintaining a $40 price target due to concerns over future growth. The firm lowered its 2027 organic growth estimate to 4.5% and its 2027 earnings per share estimate to $4.54, below consensus. BofA expects capital to flow to higher-growth large-cap companies or high-growth single-product small- and mid-cap companies instead of Conmed.
Conmed Corp (CNMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Conmed Corp (CNMD), detailing its current price momentum score, support and resistance levels. It outlines various technical indicators like MACD, RSI, and moving averages, offering buy, sell, or neutral signals for investment reference. The analysis suggests a "Buy" signal based on the cumulative assessment of these indicators.
CNMD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Conmed Corp (CNMD)'s financials, detailing its revenue breakdown, profitability margins, and a comparison with competitors. General Surgery is highlighted as the largest revenue contributor, and key financial metrics like gross margin (57.86%) and net margin (4.36%) are presented. The analysis also compares CNMD's gross margin to AVR (76.92%) and AORT (64.85%), positioning CNMD within the Medical Equipment, Supplies & Distribution industry.
Conmed Corp (CNMD) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial health analysis of Conmed Corp (CNMD), indicating a current financial score of 7.93, ranking 50 out of 204 in its industry. The company's financial status is weak, despite high operating efficiency, with recent quarterly revenue decreasing by 1.31% year-over-year and net profit declining by 129.09%. The analysis highlights specific financial dimensions including Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, noting that relevant data for some of these metrics has not yet been disclosed by the company.
Conmed Corp (CNMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
Conmed Corp (CNMD) has an earnings forecast score of 6.00, placing it 172nd in the Healthcare Equipment & Supplies industry. Analysts have an average target price of $52.00 for CNMD, with a "Hold" rating from 6 analysts. The company's expected revenue for the next quarter is $337.49 million, and its EPS for the previous quarter was $0.54 against an expectation of $0.45, with the next quarter's EPS expected at $1.11.
CONMED names John E. Gallagher as EVP & CFO, Patrick Beyer steps down as interim PFO
CONMED has appointed John E. Gallagher as Executive Vice President and Chief Financial Officer, effective July 15, 2026. This appointment will lead to Patrick Beyer and Kimberly Lockwood ceasing their interim financial reporting officer roles. Gallagher, 53, previously served as CFO at Certara and held various financial roles at other major companies.
Conmed Corp (CNMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
Conmed Corp (CNMD) has distributed a total of $96.37 million in dividends over the past five years. The article provides a detailed historical timeline of upcoming and past dividend payouts, including record dates, payment dates, and ex-dividend dates for quarterly cash dividends of $0.2 per share. No stock split events are currently recorded for CNMD.
Conmed names John Gallagher as CFO effective July 15
CONMED Corporation has announced the appointment of John E. Gallagher as its new Chief Financial Officer, effective July 15, 2026. Gallagher brings extensive financial experience from previous roles at Certara, Cue Health Inc., and Becton, Dickinson & Co. He succeeds Todd Garner, who will move into an advisory role until November 2, 2026.
Conmed Corp (CNMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Conmed Corp (CNMD) for the fiscal year 2023. It categorizes revenue by business segments, namely General Surgery and Orthopedic Surgery, and by geographical regions including the United States, Europe & Middle East & Africa, Asia Pacific, and Americas (excluding the United States). The data shows that General Surgery contributes a larger proportion of revenue compared to Orthopedic Surgery, and the United States is the primary regional revenue driver.
CONMED (NYSE: CNMD) hires John Gallagher as CFO with equity-heavy pay
CONMED Corporation has appointed John E. Gallagher as Executive Vice President and Chief Financial Officer, effective July 15, 2026. Gallagher, who brings nearly three decades of finance experience, will also serve as principal financial and principal accounting officer. His compensation package includes a $650,000 base salary, an 85% target annual bonus, equity grants under the 2025 Long-Term Incentive Plan, and a significant make-whole RSU award.
CONMED appoints John Gallagher as CFO, effective July 15 | CNMD Stock News
CONMED Corporation (NYSE: CNMD) announced the appointment of John E. Gallagher as its new Chief Financial Officer, effective July 15, 2026. Gallagher, who brings nearly three decades of financial experience in healthcare and medical technology, succeeds Todd Garner, who will remain in an advisory role until November 2, 2026. President and CEO Patrick J. Beyer highlighted Gallagher's expertise in leading global finance organizations and supporting strategic initiatives, expressing confidence in his ability to help CONMED achieve its strategic priorities and create long-term shareholder value.
Discipline and Rules-Based Execution in CNMD Response
This article provides an in-depth analysis of Conmed Corp. (NASDAQ: CNMD), highlighting near-term strong sentiment challenging persistent mid and long-term weakness. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support levels and resistance for various holding periods. The analysis suggests an exceptional risk-reward setup targeting a 12.3% gain.
CONMED Corp stock (US2074101013): Medtech mid-cap in focus after latest earnings and guidance update
CONMED Corp recently reported quarterly results and updated its guidance, drawing investor attention to its growth profile and margin trajectory in the medical device sector. The company posted year-over-year sales growth in its surgical and orthopedic portfolios and expects mid-to-high single-digit revenue growth with improved adjusted earnings per share. CONMED's business model focuses on minimally invasive surgical and orthopedic procedures, with revenue from both capital equipment and recurring consumables.
CONMED Corp stock (US2074101013): medtech growth story after latest earnings update
CONMED Corp recently reported its quarterly earnings, highlighting revenue growth driven by orthopedic and general surgery products, despite foreign exchange effects and pricing pressures. The company reaffirmed its focus on growth markets like sports medicine and advanced endoscopy while managing increased input costs and investing in innovation. Investors are watching the stock's performance, which has shown moderate volatility, as the company navigates hospital spending patterns and competitive dynamics in the medical technology sector.
CNMD - Conmed Corp Stock Price and Quote
This article provides a comprehensive overview of Conmed Corp (CNMD) stock, including its current price, key financial metrics, recent news, and analyst ratings. It details market performance, insider transactions, and company leadership, offering a snapshot of the medical technology company.
CONMED to Repurchase $645.2 Million of 2027 Convertible Notes for $637.2 Million Cash
CONMED has entered into agreements to repurchase approximately $645.2 million of its 2.25% Convertible Senior Notes due 2027 for about $637.2 million in cash. These transactions, signed on June 3, 2026, are set to close on June 15, 2026. The company's objective is to reduce outstanding debt and simplify its capital structure.
CONMED (CNMD) to buy back $645.2M of 2.25% convertible notes due 2027
CONMED Corporation announced it will repurchase approximately $645.2 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2027 for about $637.2 million in cash. These privately negotiated transactions with existing noteholders are expected to close on June 15, 2026. The move aims to reduce outstanding convertible debt and lessen potential future equity dilution.
CONMED (NYSE: CNMD) director awarded 5,772 RSUs and exercises 668 into shares
CONMED Corp director Charles Farkas reported routine equity compensation activity, receiving 5,772 Restricted Stock Units (RSUs) on June 1, 2026. On June 2, 2026, he exercised 668 RSUs into common shares, increasing his direct common stock holdings to 15,527 shares. These transactions are compensation-related under the company's 2025 Long-Term Incentive Plan.
CONMED (NYSE: CNMD) director gets 5,772 RSUs, converts 668 units
CONMED Corp director LaVerne H. Council reported equity activity, including the exercise of 668 Restricted Stock Units (RSUs) into common shares on June 2, 2026, increasing her direct common stock holdings to 4,716 shares. Additionally, on June 1, 2026, Council received a grant of 5,772 RSUs under the company's 2025 Long-Term Incentive Plan, which are generally set to vest after one year. These transactions align the director's compensation with CONMED's future performance, with no open-market purchases or sales reported.
Director Mark Kaye receives 5,772 RSUs at CONMED (NYSE: CNMD)
CONMED Corp director Mark Kaye received an award of 5,772 restricted stock units (RSUs) that generally vest 100% after one year. Additionally, 668 RSUs were converted into an equal number of common shares at no cost, reflecting equity compensation. Following these transactions, Kaye directly holds 820 shares of common stock and retains 5,772 unvested RSUs.
Director at CONMED (NYSE: CNMD) exercises 668 RSUs and receives 5,772-unit equity award
CONMED Corp director David M. Bronson exercised 668 restricted stock units (RSUs) into common shares and received a new award of 5,772 RSUs under the company’s 2025 Long-Term Incentive Plan. After these transactions, Bronson directly holds 17,909 shares of common stock. The newly granted RSUs generally vest 100% after one year.
Director at CONMED (NYSE: CNMD) receives 5,772 RSUs under 2025 incentive plan
CONMED Corp director Kim Kelderman was granted 5,772 restricted stock units (RSUs) as equity compensation under the company’s 2025 Long-Term Incentive Plan. These RSUs, each representing a contingent right to one share of common stock, generally vest 100% after one year, aligning her interests with shareholders. Following this award, Kelderman directly holds 5,772 RSUs, which may convert to common shares upon vesting.
Q1 Earnings Outperformers: CONMED (NYSE:CNMD) And The Rest Of The Surgical Equipment & Consumables - Diversified Stocks
This article reviews the Q1 earnings performance of several surgical equipment and consumables companies, including CONMED (NYSE:CNMD), Zimmer Biomet (NYSE:ZBH), STERIS (NYSE:STE), Solventum (NYSE:SOLV), and BD (NYSE:BDX). It highlights CONMED's strong beat of analyst estimates despite a year-on-year revenue decline and notes Zimmer Biomet's fastest revenue growth in the group. The article also touches on broader market concerns regarding AI and geopolitical risks impacting investment trends.
CONMED Corporation Executes First Omnibus Amendment and Increased Facility Activation Notice to Eighth Amended and Restated Credit Agreement
CONMED Corporation has filed an 8-K announcing a material amendment to its Eighth Amended and Restated Credit Agreement, effective May 27, 2026. This amendment, involving major financial institutions, modifies the company's financial obligations, capital structure, and terms for borrowing and liquidity management. Investors are advised to review the official SEC documents due to potential price-sensitive implications and changes to financial covenants.
Conmed secures $450 million term loan facility to repurchase convertible notes
Conmed Corporation announced it has secured a new $450 million senior secured delayed draw term loan facility. This facility will be used to repurchase a portion of the company's outstanding 2.25% Convertible Senior Notes due in 2026 and cover related fees. The loan matures on June 10, 2030, and its interest rates are tied to an adjusted SOFR or a base rate plus a margin, depending on Conmed’s leverage ratio.
Conmed Secures $450 Million Delayed-Draw Term Loan With JPMorgan to Repurchase 2026 Notes
Conmed has secured a $450 million senior secured delayed-draw Term A-2 loan facility with JPMorgan Chase Bank. This loan, available until June 14, 2026, and maturing in June 2030, is intended to fund the repurchase of a portion of the company's 2.25% Convertible Senior Notes due 2026 and related fees. The facility's pricing is based on SOFR or base rate, depending on leverage, and shares existing collateral and guarantees.
CONMED (NYSE: CNMD) secures $450M term loan to manage 2026 notes
CONMED Corporation has secured a new $450 million senior secured delayed draw Term A-2 Loan Facility, maturing in 2030, through an amendment to its existing credit documents. The company intends to use the proceeds to repurchase a portion of its outstanding 2.25% Convertible Senior Notes due 2026 and cover related fees. Interest on the new loans will be based on adjusted term SOFR or a base rate, with margins tied to CONMED's consolidated senior secured leverage ratio.
Why Is Conmed (CNMD) Down 3.1% Since Last Earnings Report?
Shares of Conmed (CNMD) have dropped 3.1% since its last earnings report, underperforming the S&P 500. Despite a revenue beat and increased organic sales outlook for Q1 2026, the company's adjusted EPS declined year-over-year. Investors are watching to see if this negative trend will continue or if the stock is poised for a rebound ahead of its next earnings release.
CONMED Corp stock (US2074101013): focus on growth after latest quarterly results
CONMED Corp, a medical technology company, has released its latest quarterly figures, emphasizing continued growth in minimally invasive surgery and orthopedics. The company's core business revolves around surgical devices and disposables for hospitals, with key revenue drivers in sports medicine and advanced surgical devices. The outlook focuses on profitable growth, despite macroeconomic uncertainties and cost pressures, making it relevant for investors tracking healthcare trends and surgical innovation.
CONMED Corporation Announces Results of 2026 Annual Meeting, Amended By-Laws, and Director Compensation Updates
CONMED Corporation (NYSE: CNMD) has announced significant updates including comprehensive amendments to its bylaws, which took effect on May 19, 2026, to align with Delaware law and market practices. Key changes involve advance notice provisions, director eligibility, and the introduction of proxy access for qualifying shareholders. The company also reported the results of its annual meeting, including the re-election of Patrick J. Beyer, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as its independent auditor for fiscal 2026.
Conmed appoints two directors to board effective July 1
CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026, expanding the board from seven to nine members. Martin, formerly of Johnson & Johnson, will join the audit and strategy committees. Mirviss, with extensive healthcare experience from Boston Scientific, will serve on the compensation and corporate governance committees.
New CONMED (NYSE: CNMD) directors, bylaw changes and 2026 vote outcomes
CONMED Corporation (NYSE: CNMD) made several governance updates, including expanding its board to nine directors and appointing Celine Martin and Jeff Mirviss as independent directors, effective July 1, 2026. The company also amended its bylaws to update advance notice provisions for stockholder nominations and approved the advisory vote on executive compensation and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm for fiscal 2026 at its annual meeting. Additionally, Kimberly Lockwood was appointed interim Corporate Controller and interim Principal Accounting Officer.
Celine Martin and Jeff Mirviss join ConMed board; Kimberly Lockwood named interim controller
ConMed (CNMD) has announced the appointments of Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026. Additionally, Kimberly Lockwood has been named Interim Corporate Controller and Interim Principal Accounting Officer, effective June 1, 2026. These changes are part of the board's decision to increase its size to nine directors.
J&J and Boston Scientific veterans join CONMED's board
CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026. Martin, with 30 years at Johnson & Johnson, and Mirviss, with over 35 years at Boston Scientific, bring extensive medical technology experience. Their appointments expand CONMED's board to nine directors and are expected to strengthen the company's governance and long-term strategy for patients, customers, and shareholders.
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
CONMED Corporation has announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026, increasing the board to nine members. Martin, formerly of Johnson & Johnson, will join the Audit and Strategy Committees, bringing expertise in MedTech innovation and growth. Mirviss, with extensive experience from Boston Scientific, will serve on the Compensation and Corporate Governance and Nominating Committees, focusing on portfolio leadership and operational excellence.
CONMED Corp stock (US2074101013): shares react to Q1 2026 results and updated full-year outlook
CONMED Corp's shares have been active following the company's Q1 2026 results, which showed revenue and adjusted EPS in line with expectations and a reiterated full-year outlook. The medical device company specializes in surgical products for orthopedics and general surgery, with revenue driven by arthroscopy, electrosurgery, and advanced surgical devices primarily in the US and international markets. Investors are focusing on procedure volume trends, technology adoption, competitive landscape, and the balance between innovation and profitability for future performance.
Number of shareholders of CONMED Corporation – FWB:EC8
This article provides details on the number of shareholders for CONMED Corporation (FWB:EC8) on the Frankfurt Stock Exchange. It indicates market status as closed and presents a table for period, value, change, and change percentage, though the table itself is not populated with data in the provided content. The article is primarily a stub for financial data presentation.
Oppenheimer Asset Management Inc. Has $1.27 Million Stock Holdings in CONMED Corporation $CNMD
Oppenheimer Asset Management Inc. significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 84.1% in Q4, liquidating 165,210 shares to hold 31,195 shares valued at $1.27 million. This move aligns with a cautious analyst sentiment, as JPMorgan and Wells Fargo have lowered their price targets for CONMED, leading to an average "Reduce" rating and a target price of $46.20 from MarketBeat. Despite this, CONMED reported strong Q1 earnings, beating EPS estimates ($0.89 vs. $0.82) and posting revenues of $317.1 million, even with a slight year-over-year decrease.
CONMED (NYSE:CNMD) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded CONMED (NYSE:CNMD) to a "buy" rating from a "strong-buy," reflecting softening analyst sentiment, with MarketBeat showing a consensus "Reduce" rating and a target price of $46.20. Despite this, CONMED exceeded Q1 earnings and revenue estimates, prompting management to raise its 2026 organic growth outlook and announce strategic changes like exiting the GI business and pursuing debt refinancing. Although analysts like Wells Fargo and JPMorgan have cut price targets, indicating modest near-term upside, CONMED's P/E ratio is 20.75 and it maintains a market capitalization of $1.11 billion.
CONMED Corporation (NYSE:CNMD) Q1 2026 Earnings Call Transcript
CONMED Corporation reported its Q1 2026 earnings, with total sales decreasing 1.3% but increasing 3.8% organically after divesting GI product lines. The company affirmed its strategic focus on high-growth, high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, which are key to its long-term strategy. Despite anticipated higher interest expenses from debt refinancing, CONMED maintained its full-year adjusted EPS guidance due to strong Q1 profitability and improved organic growth prospects.
CONMED (NYSE:CNMD) Price Target Lowered to $39.00 at Wells Fargo & Company
Wells Fargo & Company has lowered its price target for CONMED (NYSE:CNMD) shares to $39.00 from $42.00, maintaining an "equal weight" rating. This adjustment follows CONMED's Q1 earnings beat, where it delivered $0.89 EPS against an estimated $0.82 and $317 million in revenue, exceeding the $310.6 million estimate. Despite the strong Q1 performance and raised organic growth outlook, the company faces a near-term revenue headwind due to a strategic exit from certain GI products.
CNMD SEC Filings - Conmed Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Conmed Corp (CNMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It features AI-powered tools to interpret and summarize these documents, highlighting key financial data, operational performance, and strategic actions. The information is crucial for understanding CONMED's financial condition and market activities.
